CLOs on the Move

ProMetic

www.prometic.com

 
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparation, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.prometic.com
  • 440 Boul. Armand-Frappier Suite 300
    Laval, QC CAN H7V 4B4
  • Phone: 450.781.0115

Executives

Name Title Contact Details

Similar Companies

Ion Labs

Ion Labs is a cGMP Certified & FDA registered private label and contract manufacturer of dietary supplements, OTCs, pet supplements, and skin care products.

The Morel Company

A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.

Centered Health

Centered Health is a tranquil, rehabilitation haven for adolescents struggling with addiction, substance abuse and co-occurring mental health disorders. Our beautiful residential facility is based in Malibu, California, with panoramic views of the ...

Leiters

Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.